Financial Performance - The company's operating revenue for Q3 2023 was ¥2,788,944,577.10, representing an increase of 11.40% compared to the same period last year[4]. - Net profit attributable to shareholders for Q3 2023 reached ¥619,619,074.86, a significant increase of 76.86% year-over-year[4]. - The net profit excluding non-recurring gains and losses for Q3 2023 was ¥515,375,602.31, up 44.56% from the previous year[4]. - The basic earnings per share for Q3 2023 was ¥0.44, reflecting a growth of 75.52% compared to the same quarter last year[4]. - Total operating revenue for the first three quarters of 2023 reached ¥8,337,759,691.76, a significant increase from ¥6,901,462,229.91 in the same period of 2022, representing a growth of approximately 20.8%[18]. - Net profit for the third quarter of 2023 was ¥1,498,941,843.85, up from ¥717,051,000.01 in the same quarter of 2022, reflecting a growth of approximately 108.5%[20]. - Earnings per share for the third quarter of 2023 were ¥1.05, compared to ¥0.50 in the same quarter of 2022, marking a 110% increase[20]. - The net profit for the first three quarters of 2023 was ¥1,927,763,538.12, compared to ¥766,296,786.05 in 2022, indicating a significant increase of about 152.5%[27]. Assets and Liabilities - The total assets at the end of Q3 2023 amounted to ¥17,869,252,520.85, an increase of 10.12% from the end of the previous year[5]. - The total liabilities as of September 30, 2023, are 5.800 billion RMB, slightly up from 5.705 billion RMB at the end of 2022[16]. - The total liabilities as of the end of the third quarter of 2023 amounted to ¥7,136,259,263.63, an increase from ¥6,605,796,858.33 in the previous year, representing a growth of about 8%[19]. - The total equity attributable to shareholders of the parent company increased to ¥10,612,054,930.50 from ¥9,505,536,761.16, reflecting a growth of approximately 11.6%[19]. - The company's total equity as of the end of Q3 2023 was ¥8,014,156,559.63, compared to ¥6,448,925,919.86 in 2022, representing a growth of about 24.3%[26]. - The total assets as of the end of the third quarter of 2023 were ¥17,869,252,520.85, compared to ¥16,227,718,923.75 in the previous year, indicating a growth of about 10.1%[19]. Cash Flow - The net cash flow from operating activities for Q3 2023 decreased by 60.82% to ¥115,363,804.92 due to increased payments for raw material purchases[4][9]. - The net cash flow from operating activities for the first three quarters of 2023 was CNY 293,656,895.75, an increase of 32% compared to CNY 223,223,765.53 in the same period of 2022[22]. - Total cash inflow from operating activities reached CNY 8,532,383,516.92, up 37% from CNY 6,224,407,344.64 year-on-year[22]. - The company reported a net cash outflow from investing activities of CNY -402,676,809.04, compared to CNY -169,680,929.70 in the previous year, indicating increased investment expenditures[23]. - Cash inflow from financing activities was CNY 1,804,400,689.20, down 45% from CNY 3,308,444,332.65 in the same period last year[23]. Segment Performance - The smart distribution board segment's revenue grew by 17.75% year-over-year, contributing to the overall revenue increase[9]. - The medical services segment's revenue increased by 34.72% year-over-year, with net profit rising by 53.07%[9]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 17,995, with the largest shareholder, Aux Group Co., Ltd., holding 457,719,653 shares, accounting for 32.41%[10]. - The company has no pledged, marked, or frozen shares among the top shareholders[10]. Research and Development - Research and development expenses for the third quarter of 2023 were ¥319,474,410.37, compared to ¥247,539,084.25 in the same quarter of 2022, indicating an increase of about 29%[19]. - Research and development expenses for the first three quarters of 2023 totaled ¥90,325,485.92, up from ¥65,008,094.08 in 2022, which is an increase of approximately 38.9%[27].
三星医疗(601567) - 2023 Q3 - 季度财报